{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T14:24:14Z","timestamp":1695911054997},"reference-count":9,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"published-print":{"date-parts":[[1994,3,1]]},"DOI":"10.1136\/jnnp.57.3.371","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T22:20:59Z","timestamp":1226355659000},"page":"371-372","source":"Crossref","is-referenced-by-count":4,"title":["Benign intracranial hypertension associated with the withdrawal of a non-ergot dopamine agonist"],"prefix":"10.1136","volume":"57","author":[{"given":"S L","family":"Atkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E A","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L D","family":"Blumhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","article-title":"Drugs five years later","volume":"100","author":"Vance, M.L.; Evans, W.S.; Thorner, M.O.","year":"1984","unstructured":"Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med 1984;100:78-91.","journal-title":"Bromocriptine. Ann Intern Med"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2265.1989.tb01263.x","article-title":"Effect of CV 205 502 in hyperprolactinaemic patients intolerant of bromocriptine","volume":"31","author":"Newman, C.B.; Cragun, JR, Kleinberg; D.L.","year":"1989","unstructured":"Newman CB, Cragun JR, Kleinberg DL. Effect of CV 205 502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol 1989;31:391-400.","journal-title":"Clin Endocrinol"},{"key":"ref_3","first-page":"13","article-title":"Idiopathic intracranial hypertension","volume":"17","author":"Tessler, Z.; Marcus, M.","year":"1991","unstructured":"Tessler Z, Marcus M. Idiopathic intracranial hypertension. Comp Ther 1991;17:13-7.","journal-title":"Comp Ther"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-2007-999635","article-title":"Pseudotumor cerebri and pregnancy","volume":"6","author":"Katz, V.L.; Peterson, R.; Cefalo, R.C.","year":"1989","unstructured":"Katz VL, Peterson R, Cefalo RC. Pseudotumor cerebri and pregnancy. AmJ Perinatol 1989;6:442-5.","journal-title":"AmJ Perinatol"},{"key":"ref_5","first-page":"535","article-title":"Neurological disorders","volume-title":"Textbook of adverse drug reactions","author":"Blain, P.G.; Lane, R.G.M.","year":"1991","unstructured":"Blain PG, Lane RGM. Neurological disorders. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991:535-66."},{"key":"ref_6","first-page":"305","article-title":"A novel octahydrobenzyl(q)quinoline, CV 205 502 with potent dopamine agonist properties","volume-title":"85","author":"Gaillard, R.C.; Nordmann, R.; Petcher, T.J.; Brownwell, J.","year":"1986","unstructured":"Gaillard RC, Nordmann R, Petcher TJ, Brownwell J. A novel octahydrobenzyl(q)quinoline, CV 205 502 with potent dopamine agonist properties. In: Molinatti GM, Martini L, eds. Endocrinology '85. Amsterdam: Elsevier, 1986:305-8."},{"key":"ref_7","first-page":"891","article-title":"Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV 205-502","volume":"295","author":"Barnett, P.S.; Palazidou, E.; Miell, J.P.","year":"1991","unstructured":"Barnett PS, Palazidou E, Miell JP, et al. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV 205-502. Q J Med 1991;295:891-906.","journal-title":"Q J Med"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1526-4610.1976.hed1603109.x","article-title":"Bromocriptine in migraine","volume":"16","author":"Hockaday, J.M.; Peet, K.M.; Hockaday, T.D.","year":"1976","unstructured":"Hockaday JM, Peet KM, Hockaday TD. Bromocriptine in migraine. Headache 1976;16:109-14.","journal-title":"Headache"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1526-4610.1980.hed2002099.x","article-title":"Hyper-responsiveness of migraine patients to the hypotensive action of bromocriptine","volume":"20","author":"Fanciullacci, M.; Michelacci, S.; Curradi, C.; Sicuteri, F.","year":"1980","unstructured":"Fanciullacci M, Michelacci S, Curradi C, Sicuteri F. Hyper-responsiveness of migraine patients to the hypotensive action of bromocriptine. Headache 1980;20: 99-102.","journal-title":"Headache"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp.57.3.371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T02:46:21Z","timestamp":1601088381000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp.57.3.371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,3,1]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,3,1]]}},"URL":"https:\/\/doi.org\/10.1136\/jnnp.57.3.371","relation":{},"ISSN":["0022-3050"],"issn-type":[{"value":"0022-3050","type":"print"}],"subject":[],"published":{"date-parts":[[1994,3,1]]}}}